Peer Review reports
From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
| Original Submission | ||
|---|---|---|
| 21 Jun 2019 | Submitted | Original manuscript |
| 7 Jul 2019 | Author responded | Author comments - Didar Yanardag Acik |
| Resubmission - Version 2 | ||
| 7 Jul 2019 | Submitted | Manuscript version 2 |
| 13 Aug 2019 | Reviewed | Reviewer Report - Bruno Reversade |
| 27 Aug 2019 | Reviewed | Reviewer Report - RAKESH KUMAR |
| 14 Sep 2019 | Author responded | Author comments - Didar Yanardag Acik |
| Resubmission - Version 3 | ||
| 14 Sep 2019 | Submitted | Manuscript version 3 |
| 17 Sep 2019 | Reviewed | Reviewer Report - Bruno Reversade |
| 19 Oct 2019 | Author responded | Author comments - Didar Yanardag Acik |
| Resubmission - Version 4 | ||
| 19 Oct 2019 | Submitted | Manuscript version 4 |
| 23 Oct 2019 | Author responded | Author comments - Didar Yanardag Acik |
| Resubmission - Version 5 | ||
| 23 Oct 2019 | Submitted | Manuscript version 5 |
| 25 Oct 2019 | Author responded | Author comments - Didar Yanardag Acik |
| Resubmission - Version 6 | ||
| 25 Oct 2019 | Submitted | Manuscript version 6 |
| Publishing | ||
| 1 Nov 2019 | Editorially accepted | |
| 12 Nov 2019 | Article published | 10.1186/s12885-019-6325-6 |
You can find further information about peer review here.